Sino Biopharmaceutical (01177.HK): TRD205 (AT2R Antagonist) Included in CDE’s Breakthrough Therapy Designation List
NewTimeSpace News: On 14 July 2026, Sino Biopharmaceutical (01177.HK) released an announcement. TRD205, a proprietary Class 1 new AT2R antagonist developed by the Group’s subsidiary Beijing Tide Pharmaceutical, has finished its Phase II clinical study for chronic postoperative neuropathic pain (CPSNP). Encouraging clinical outcomes qualified the candidate for inclusion in the CDE breakthrough therapy list.
As disclosed in the announcement, TRD205 is a highly selective AT2R antagonist generated on Sino Biopharmaceutical’s second-generation AI drug discovery platform. Novel molecules are directly created by AI without relying on known ligand structures. Its core innovation lies in its high selectivity for peripheral AT2R receptors. It delivers multimodal analgesia by restraining macrophage migration and downregulating the expression of pain-related ion channels, while sidestepping central nervous system side effects commonly seen in traditional painkillers such as drowsiness and dizziness.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Sino Biopharmaceutical (01177.HK): Second-Generation Flurbiprofen Patch Approved for Marketing
- SBP GROUP (01177.HK): TQ-A3334, Bepirovirsen Data Picked for AASLD
- SBP GROUP (01177.HK): TQC3721 Phase III completes enrolment
- RED AVENUE NEW MATERIALS (603650.SH): Passes HKEX Listing Hearing with Haitong International as Sole Sponsor
